Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study

Core Insights - Sanofi (SNY) announced that its late-stage study of venglustat for treating type 3 Gaucher disease (GD3) met all primary and most secondary endpoints [1][9] Group 1: Study Overview - The phase III LEAP2MONO study evaluated the safety and efficacy of once-daily oral venglustat compared to intravenous enzyme replacement therapy (ERT) in 43 patients aged 12 years and older with GD3 [2] - Primary endpoints included assessing changes in neurological function using the modified Scale for Assessment and Rating of Ataxia (SARA) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) from baseline to week 52 [2] Group 2: Study Results - The study met both primary endpoints, showing statistically significant and clinically meaningful improvements in neurological symptoms at 52 weeks compared to ERT [3] - Venglustat performed comparably to ERT on non-neurological outcomes such as spleen and liver volume and hemoglobin levels, which were important secondary endpoints [4] Group 3: Safety and Tolerability - Venglustat was well-tolerated with no new safety concerns observed, although mild side effects such as headache, nausea, spleen enlargement, and diarrhea were noted [4] Group 4: Regulatory and Market Context - Following the successful phase III data, Sanofi is proceeding with global regulatory filings for venglustat to treat GD3 [5] - Currently, there are no approved treatments for GD3, highlighting the potential market opportunity for venglustat [10] Group 5: Competitive Landscape - Sanofi's commercial portfolio for treating Gaucher disease includes two globally marketed drugs, Cerezyme and Cerdelga, which offer enzyme replacement and oral treatment options, respectively [13]